Prognosis
Biogen to Make Experimental ALS Drug Available to Dying Patients
- Compassionate-use program for tofersen will start in July
- Early-access move comes after patients pushed for treatment
This article is for subscribers only.
Biogen Inc. said it will make an experimental medicine for Lou Gehrig’s disease available to some people who are dying of the incurable illness starting in July, following months of pressure from patients who had no other treatment options.
The drug, known as tofersen, will be offered to the most rapidly progressing patients after researchers complete a key study this summer, the company said in a statement posted on its website.